Complementation of two mutant p53: Implications for loss of heterozygosity in cancer

被引:8
|
作者
Demidenko, ZN
Fojo, T
Blagosklonny, MV
机构
[1] New York Med Coll, Brander Canc Res Inst, Valhalla, NY 10595 USA
[2] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源
FEBS LETTERS | 2005年 / 579卷 / 10期
关键词
cancer; p53; tumor suppressor;
D O I
10.1016/j.febslet.2005.03.012
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Remarkably, a cancer cell rarely possesses two mutant p53 proteins. Instead, mutation of one allele is usually associated with loss of the second p53 allele. Why do not two mutant p53 co-exist? We hypothesize that two different p53 may complement each other, when expressed at equal levels. By titrating trans-deficient and DNA-binding-deficient p53 in cells with mutant p53 and by co-transfecting distinct mutant p53 in p53-null cells, we demonstrated activation of p53-dependent transcription. We suggest that, due to complementation of two mutant p53, cancer cells need to delete the second p53 allele rather than mutate it. (c) 2005 Federation of European Biochemical Societies. Published by Elsevier B.Ni. All rights reserved.
引用
收藏
页码:2231 / 2235
页数:5
相关论文
共 50 条
  • [31] LOSS OF HETEROZYGOSITY AT THE P53 AND RB LOCI IN ULCERATIVE-COLITIS
    HARPAZ, N
    YIN, J
    GREENWALD, BJ
    HUANG, Y
    MCDANIEL, T
    NEWKIRK, C
    RESAU, JH
    MELTZER, SJ
    LABORATORY INVESTIGATION, 1992, 66 (01) : A42 - A42
  • [32] Elevated frequency of Aprt loss of heterozygosity in p53 null mice
    Shao, C
    Stambrook, PJ
    Tischfield, JA
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (04) : A81 - A81
  • [33] Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma
    Grote, HJ
    Schneider-Stock, R
    Neumann, W
    Roessner, A
    VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 2000, 436 (05): : 494 - 497
  • [34] Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma
    H. J. Grote
    Regine Schneider-Stock
    W. Neumann
    A. Roessner
    Virchows Archiv, 2000, 436 : 494 - 497
  • [35] Mutant p53 as an Antigen in Cancer Immunotherapy
    Sobhani, Navid
    D'Angelo, Alberto
    Wang, Xu
    Young, Ken H.
    Generali, Daniele
    Li, Yong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11) : 1 - 21
  • [36] Mutant p53 as a guardian of the cancer cell
    Fiamma Mantovani
    Licio Collavin
    Giannino Del Sal
    Cell Death & Differentiation, 2019, 26 : 199 - 212
  • [37] Mutant p53 as a target for cancer treatment
    Duffy, Michael J.
    Synnott, Naoise C.
    Crown, John
    EUROPEAN JOURNAL OF CANCER, 2017, 83 : 258 - 265
  • [38] Targeting mutant p53 for cancer therapy
    Oren, Moshe
    Tal, Perry
    Rotter, Varda
    AGING-US, 2016, 8 (06): : 1159 - 1160
  • [39] Mutant p53 reactivation restricts the protumorigenic consequences of wild type p53 loss of heterozygosity in Li-Fraumeni syndrome patient-derived fibroblasts
    Agarwal, Himanshi
    Tal, Perry
    Goldfinger, Naomi
    Chattopadhyay, Esita
    Malkin, David
    Rotter, Varda
    Attery, Ayush
    CELL DEATH AND DIFFERENTIATION, 2024, 31 (07): : 855 - 867
  • [40] p53 Isoforms and Their Implications in Cancer
    Vieler, Maximilian
    Sanyal, Suparna
    CANCERS, 2018, 10 (09)